Libri di Bernard Lerer

This book presents a comprehensive overview of recent advances in evidence-based pharmacological treatment of psychiatric disorders. There have been very significant developments in our understanding of the methods for systematically reviewing literature, assessing clinical trials and optimising decision making. The book explores these issues and applies the lessons learned to the practical management of major psychiatric conditions, addressing issues such as selecting the best first-line psychopharmacological intervention for a particular disorder, how long a particular intervention should be continued, and identifying the next-best treatment strategy should the first agent fail. Conditions covered include, amongst others, depression, schizophrenia, panic, PTSD, OCD, ADHD and eating disorders. The potential for complications as a result of adverse interactions between drugs is also examined. These issues lie at the heart of clinical psychopharmacology and the book will therefore appeal to all practising clinicians, whether in a primary care or a specialist mental health setting.

Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.